Anatomical segmentectomy versus wedge resection in high-risk operable patients with clinical stage IA non-small cell lung cancer: A randomized phase III trial. (JCOG1909, ANSWER)
- Conditions
- clinical stage IA non-small cell lung cancer
- Registration Number
- JPRN-UMIN000040089
- Lead Sponsor
- Japan Clinical Oncology Group (JCOG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 370
Not provided
(1) History of synchronous or metachronous (within 2 years) malignancies with 5-year relative survivals of less than 95% at the time of diagnosis.) (2) Active infection requiring systemic therapy. (3) Fever of higher than 38.0 degrees Celsius at the time of enrollment. (4) Pregnant, possibly pregnant, within 28 days after delivery, breastfeeding female or males expecting conception of their child. (5) Psychiatric illnesses or symptoms affecting daily lives. (6) Systemic administration of steroids or immunosuppressive agents either orally or intravenously. (7) Uncontrollable diabetes (HbA1c > 8%). (8) Uncontrollable hypertension. (9) Unstable angina (diagnosis or worsening of chest pain within 3 weeks) or history of myocardial infarction within 6 months prior to enrollment. (10) Uncontrollable heart valve disease, dilated cardiomyopathy, or hypertrophic cardiomyopathy. (11) Diagnoses of interstitial pneumonia, pulmonary fibrosis, or both, on chest CT.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method